Diversified Healthcare Company Reveals Clinical Trial Advancements of Its AI-Powered Technology

Ainos, Inc. (NASDAQ: AIMD, AIMDW), a diversified healthcare company focusing on novel AI-powered point-of-care testing (POCT) and VELDONA low-dose interferon therapeutics, has recently announced advancements in the clinical trials of its "Ainos Flora" device. This volatile organic compound (VOC) POCT device employs transformative AI-powered digital nose ("AI Nose") technology to provide rapid, non-invasive detection of bacterial, fungal, and certain common sexually transmitted infections (STIs) in women. The clinical trials are currently being conducted at four leading medical centers in Taiwan. $Ainos (AIMD.US)$